TRICARE Prior Authorization Request Form for
pirtobrutinib (Jaypirca)

JOHNS HOPKINS
HEALTH PLANS
7231 Parkway Drive, Suite 100, Hanover, MD 21076

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

USFHP Pharmacy Prior Authorization Form

To be completed by Requesting provider	
Drug Name:	Strength:
Dosage/Frequency (SIG):	Duration of Therapy:

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step 1

Please complete patient and physician information (please print):

Patient Name: _____ Physician Name: _____

Address: _____ Address: _____

_____ _____

Sponsor ID # _____ Phone #: _____

Date of Birth: Secure Fax #:

Step 2

Please complete the clinical assessment:

1. Is the patient GREATER THAN or EQUAL to 18 years of age?	☐ Yes Proceed to question **2**	☐ No **STOP** **Coverage not approved**
2. Is the requested medication being prescribed by or in consultation with a hematologist or oncologist?	☐ Yes Proceed to question **3**	☐ No **STOP** **Coverage not approved**
3. Does the patient have pathologically confirmed relapsed or refractory mantle cell lymphoma (MCL)?	☐ Yes Proceed to question **8**	☐ No Proceed to question **4**
4. Does the patient have chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)?	☐ Yes Proceed to question **5**	☐ No Proceed to question **6**
5. Has the patient received at least two prior lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor and a B-cell leukemia/lymphoma 2 protein (BCL-2) inhibitor?	☐ Yes Proceed to question **8**	☐ No **STOP** **Coverage not approved**
6. What is the diagnosis or indication?	_____ Proceed to question **7**	

TRICARE Prior Authorization Request Form for **pirtobrutinib (Jaypirca)**

7. Is the diagnosis cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B recommendation?	☐ Yes Proceed to question **8**	☐ No **STOP** **Coverage not approved**
8. Will the patient be monitored for bleeding, infection (including opportunistic infection), cardiac arrhythmias, secondary primary malignancies, and cytopenias?	☐ Yes Proceed to question **9**	☐ No **STOP** **Coverage not approved**
9. Will the patient use sun protection in sun-exposed areas?	☐ Yes Proceed to question **10**	☐ No **STOP** **Coverage not approved**
10. What is the patient's gender?	☐ Female Proceed to question **11**	☐ Male **Sign and date below**
11. Is the patient of childbearing potential?	☐ Yes Proceed to question **12**	☐ No **Sign and date below**
12. Does the patient agree to use effective contraception before starting treatment, during treatment and for at least 1 week after cessation of therapy?	☐ Yes Proceed to question **13**	☐ No **STOP** **Coverage not approved**
13. Is the patient pregnant?	☐ Yes **STOP** **Coverage not approved**	☐ No Proceed to question **14**
14. Has it been confirmed that the patient is not pregnant by negative hCG (human chorionic gonadotropin)?	☐ Yes Proceed to question **15**	☐ No **STOP** **Coverage not approved**
15. Will the patient avoid breastfeeding during treatment and for at least 1 week after the cessation of treatment?	☐ Yes **Sign and date below**	☐ No **STOP** **Coverage not approved**

Step 3 **I certify the above is true to the best of my knowledge.** Please sign and date:

Prescriber Signature _____ Date _____

[26 June 2024]

For Internal Use Only	
☐ Approved:	Duration of Approval: _____month(s)
☐ Denied:	Authorized By:
☐ Incomplete/Other:	PA#:
Date Faxed to MD:	Date Decision Rendered: